Testing MRG003 alone or with putrelimab for recurrent or metastatic salivary gland cancer

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

This trial tests whether MRG003, by itself or combined with putrelimab, can help people with recurrent or metastatic salivary gland cancers that show EGFR on their tumors.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Fudan University (Academic / other)
• Drugs / interventions: Ptoridimab, chemotherapy, radiation, prednisone, pertuzumab
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT07464366 on ClinicalTrials.gov

What this trial studies

This is a single-center, open-label Phase II trial with four sequential cohorts enrolling patients with recurrent or metastatic adenoid cystic carcinoma (ACC) and other salivary gland carcinomas. Cohorts 1 and 2 will receive intravenous MRG003 alone for ACC and non-ACC subtypes respectively, and after those enrollments are completed, Cohorts 3 and 4 will receive MRG003 combined with putrelimab for ACC and non-ACC subtypes. Enrollment requires histopathologic confirmation of salivary gland cancer, documented EGFR expression, available tumor tissue, and at least 12 weeks expected survival; ACC and acinic cell carcinoma patients must show recent progression or worsening symptoms. The trial is non-randomized and exploratory, focusing on safety and signs of anti-tumor activity rather than comparing against a control arm.

Who should consider this trial

Good fit: Adults (18+) with recurrent or metastatic salivary gland carcinoma not amenable to curative surgery or radiotherapy, with tumor EGFR expression and available tissue for testing, are the intended candidates.

Not a fit: Patients whose tumors do not express EGFR, who have very limited life expectancy, or who are eligible for standard curative treatment are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, the treatment could shrink tumors or slow disease growth and prolong the time patients live without worsening symptoms.

How similar studies have performed: Prior early-phase studies of EGFR-directed antibody-drug conjugates and PD‑1 combinations in salivary gland cancers have shown mixed signals but no established standard, so this combination remains exploratory.

Eligibility criteria

Inclusion Criteria:

1. The subject must provide voluntary informed consent and agree to comply with all protocol requirements.
2. The subject must be at least 18 years of age on the date of informed consent form signing, with no restrictions based on gender.
3. Expected survival duration of at least 12 weeks.
4. Histopathologically confirmed recurrent or metastatic salivary gland cancer that cannot be treated with curative surgery or radiotherapy, including major subtypes such as adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma; and immunohistochemically confirmed EGFR expression or positivity.
5. Patients diagnosed with adenoid cystic carcinoma (ACC) or acinic cell carcinoma must meet one of the following criteria: evidence of radiographic progression within 6 months prior to enrollment, or new or worsening tumor-related symptoms.
6. The subject must be able to provide a tumor tissue specimen-either from the primary or metastatic site-for pathological evaluation. Acceptable specimens include formalin-fixed paraffin-embedded blocks, paraffin-embedded sections, or fresh tissue sections. If archived tissue is unavailable, a new biopsy must be performed.
7. According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, the subject must have at least one measurable lesion at baseline, defined as a lesion with a longest diameter ≥10 mm on CT imaging (or a short axis ≥15 mm for lymph nodes). Lesions previously irradiated may be considered target lesions if there is radiological evidence of progression; however, non-irradiated lesions are preferred.
8. The Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 within 7 days prior to the first administration of study drug.
9. Organ function must meet the following criteria within 7 days prior to dosing:

   * Hematologic function: Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and hemoglobin ≥90 g/L. Subjects must not have received blood or platelet transfusions within 14 days prior to first dosing, nor growth factor support (e.g., granulocyte colony-stimulating factor or erythropoiesis-stimulating agents) within 7 days prior to first dosing.
   * Hepatic function: For patients without liver metastases, total serum bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN. For patients with liver metastases, TBIL ≤1.5 × ULN, and ALT and AST ≤5 × ULN.
   * Coagulation function: International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (aPTT) ≤1.5 × ULN. Stable low-dose anticoagulation (e.g., aspirin 100 mg daily) is permitted.
   * Renal function: Creatinine clearance (CrCl) ≥50 mL/min, calculated using the Cockcroft-Gault formula.
10. Male subjects with reproductive potential and female subjects of childbearing potential must agree to use effective contraception from the time of informed consent through at least 6 months after the final dose of investigational product. Female subjects are considered of childbearing potential if they are premenopausal or within 2 years of menopause. A negative serum pregnancy test is required for all female subjects of childbearing potential within 7 days prior to the first administration of study drug.

Exclusion Criteria:

1. A history of other malignancies within the past five years is exclusionary, except for adequately treated and cured cervical carcinoma in situ, thyroid cancer (excluding medullary or anaplastic types), or basal cell carcinoma of the skin.
2. Prior receipt of any of the following treatments:

   * Administration of an antibody-drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload within 3 months prior to first dose;
   * Exposure to any investigational agent in a clinical trial within 28 days prior to first dose;
   * Receipt of systemic anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, or other modalities) within 28 days prior to first dose;
   * Undergone major surgery within 28 days prior to first dose without full recovery, or scheduled to undergo major surgery during the first 12 weeks following initiation of study treatment.
3. Patients with HER2-positive status at baseline who have not received HER2-targeted or combination therapy (including HER2 monoclonal antibody-based combinations, HER2 ADCs, or HER2-targeted small-molecule agents; receipt of any one of these is acceptable for enrollment).
4. Presence of symptomatic central nervous system (CNS) metastases or leptomeningeal disease; or history of CNS metastasis treatment within 3 months prior to first dose.
5. Clinically symptomatic pleural, peritoneal, or pericardial effusion requiring puncture drainage; except for patients with stable disease after symptomatic treatment, as determined by the investigator to be eligible for enrollment.
6. Any severe or uncontrolled systemic illness, as determined by the investigator, including but not limited to poorly controlled hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg), inadequately controlled diabetes mellitus, or evidence of active bleeding.
7. Poorly controlled cardiac disease, including heart failure of New York Heart Association (NYHA) class ≥2, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment.
8. Active or uncontrolled infection, including:

   * Hepatitis B virus (HBV): HBsAg positive and HBV DNA ≥2,000 IU/mL (with exclusion of drug-induced or other non-viral causes of hepatitis);
   * Hepatitis C virus (HCV): anti-HCV antibody positive and detectable HCV RNA above the assay's lower limit of quantification;
   * Human immunodeficiency virus (HIV) infection;
   * Uncontrolled bacterial, viral (non-HBV/HCV), fungal, rickettsial, or parasitic infections, unless resolved with appropriate treatment prior to first administration of study drug.
9. History of hypersensitivity to Ptoridimab or any excipient in MRG003 (histidine, histidine hydrochloride, sucrose, mannitol, polysorbate 80), or prior grade ≥3 hypersensitivity reaction to monoclonal antibodies or other large protein therapeutics.
10. Known history of primary immunodeficiency or active autoimmune disease requiring immunosuppressive therapy; current or recent (within 2 weeks before enrollment) use of systemic immunosuppressants or corticosteroids at a dose equivalent to ≥10 mg/day prednisone.

    Note: The following are permitted: type 1 diabetes mellitus with stable control; hypothyroidism managed with hormone replacement; vitiligo or psoriasis not requiring systemic therapy; use of topical or inhaled corticosteroids; or short-term (≤7 days) systemic corticosteroid use for non-autoimmune indications such as allergy prophylaxis or acute inflammation.
11. History of or concurrent moderate-to-severe interstitial lung disease, radiation pneumonitis, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, or symptomatic bronchospasm.
12. Failure to recover from prior anti-cancer therapy-related toxicities to Grade ≤1 according to NCI-CTCAE v5.0, excluding alopecia, any degree of skin hyperpigmentation, or stable Grade 2 hypothyroidism on hormone replacement.
13. Peripheral neuropathy of Grade \>1.
14. Any other condition that, in the investigator's judgment, contraindicates participation in the study, including substance abuse (e.g., alcoholism, drug addiction), or inability to comply with study procedures.

Where this trial is running

Shanghai, Shanghai Municipality

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Dongmei Ji, Medical Doctor

Conditions Salivary Gland Carcinomas